Japanese Knotweed for Resveratrol & Longevity

When you buy a resveratrol supplement — from any brand, in any form — you are almost certainly buying Japanese knotweed root extract. The polyphenol that made red wine famous is not commercially extracted from grapes; the concentration is far too low and the cost would be prohibitive. Instead, virtually every capsule of trans-resveratrol on the global market is purified from Polygonum cuspidatum rhizome, where the molecule is concentrated to dramatically higher levels than in any other commercially harvestable plant. This page traces the chain that started with Konrad Howitz and David Sinclair's 2003 Nature paper, ran through Sirtris Pharmaceuticals and the GSK acquisition, and ended with a sober reassessment that resveratrol is a real but modest tool — not a fountain of youth. We also address the central practical problem: oral resveratrol has terrible bioavailability, and most of what you swallow is glucuronidated to inactive metabolites within an hour.

Table of Contents

  1. Japanese Knotweed: The World's Resveratrol Supply
  2. The Howitz 2003 Nature Paper — SIRT1 Activation
  3. Sinclair, Baur, and the 2006 Mouse Lifespan Studies
  4. How SIRT1 Actually Works (The Caloric Restriction Connection)
  5. The Resveratrol — NAD — Sirtuin Axis
  6. The Bioavailability Problem (Why Oral Dosing Underperforms)
  7. Polydatin as a Bioavailability Workaround
  8. Human Clinical Trials — The Modest Reality
  9. Stack Combinations (NR, NMN, Spermidine, Metformin)
  10. Practical Dosing for Longevity Use
  11. Cautions and Realistic Expectations
  12. Key Research Papers
  13. Connections

Japanese Knotweed: The World's Resveratrol Supply

Resveratrol exists in measurable quantities in several plant species — grapes (skin and seeds), peanuts, blueberries, cranberries, mulberries, and cocoa — but the concentrations are low enough that extracting commercially meaningful quantities from any of these sources is economically impractical. A glass of red wine contains roughly 0.5 to 2 mg of resveratrol, depending on grape variety, sun exposure of the vineyard, and fermentation duration. To get the 250 mg used in most clinical trials, you would need to drink between 30 and 100 bottles of wine per day — obviously absurd.

Japanese knotweed root, by contrast, contains trans-resveratrol at concentrations of approximately 0.5% to 2% by dry weight, with some cultivars and harvest conditions pushing higher. Combined with polydatin (the glycoside form, present at higher concentrations still — sometimes 4% to 8% by dry weight), the total resveratrol-equivalent content of dried knotweed root is in the range of 5% to 10%. That is high enough to support commercial extraction, and as a result every major supplement manufacturer worldwide that sells purified resveratrol — whether marketed as "trans-resveratrol," "resveratrol," or under proprietary brand names — starts with knotweed.

The standard commercial products fall into a few categories. 8% standardized extracts retain a substantial fraction of the original knotweed root matrix (anthraquinones, additional stilbenes, flavonoids) alongside the resveratrol — closer to a traditional herbal preparation. 50% standardized extracts are more refined but still contain some accompanying constituents. 98% (or "trans-resveratrol") products are purified to the point where they are essentially the isolated molecule with only trace amounts of plant matrix, indistinguishable in pharmacological terms from synthetic resveratrol.

The choice matters. If you are using resveratrol specifically for the SIRT1-mediated longevity effects studied by Sinclair, the purified 98% products are the most relevant. If you are using knotweed as part of the broader Buhner Lyme protocol or for traditional Chinese medicine indications, the lower-percentage standardized extracts (or whole-root powder/tincture) retain the synergistic anthraquinones and flavonoids that contribute to the multi-mechanism profile.

Back to Table of Contents

The Howitz 2003 Nature Paper — SIRT1 Activation

The modern resveratrol story begins with a high-throughput screening project run by Konrad Howitz at BIOMOL Research Laboratories in collaboration with David Sinclair's lab at Harvard Medical School. The team screened a library of small molecules looking for compounds that could activate the human sirtuin SIRT1. SIRT1 was of intense interest because its yeast homolog Sir2 had been shown to extend yeast replicative lifespan, and a unifying theory was emerging that caloric restriction extended lifespan across species partly through sirtuin activation.

The screen identified several plant polyphenols as candidate SIRT1 activators. Of those, trans-resveratrol was the most potent, lowering the apparent Km of SIRT1 for its acetylated substrate by about 35-fold in the in-vitro assay. The paper went on to show that resveratrol extended replicative lifespan in Saccharomyces cerevisiae by approximately 70% — a dramatic effect for a single compound at micromolar concentration. The 2003 Nature paper (Howitz KT et al., "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan") became one of the most-cited papers in the longevity research field and effectively launched resveratrol as a household word.

The paper drew intense interest from both academic researchers and the supplement industry. Within a year, resveratrol supplements began appearing on US shelves, and within five years David Sinclair had co-founded Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline in 2008 for $720 million. The Sirtris bet was that resveratrol (or improved sirtuin-activating compounds, SIRT1 activators or STACs) could be developed into drugs for diabetes, metabolic syndrome, and age-related disease.

The story has been complicated by subsequent technical challenges. The Pacholec 2010 paper (Pfizer) reported that resveratrol does not directly activate purified SIRT1 in a substrate-independent assay — the apparent activation in the original Howitz assay was an artifact of using a fluorogenic peptide substrate (the "Fluor-de-Lys" assay) that resveratrol bound directly. This controversy is still partly unresolved; subsequent work has shown that resveratrol can activate SIRT1 against native substrates under appropriate conditions, and that AMPK activation by resveratrol indirectly raises NAD+ levels which activate SIRT1 through canonical cofactor coupling. The net effect — sirtuin pathway activation in vivo — appears to be real, even if the precise molecular mechanism is more complicated than "direct allosteric activator" first suggested.

Back to Table of Contents

Sinclair, Baur, and the 2006 Mouse Lifespan Studies

The next pivotal paper came in 2006 from Sinclair's lab. Baur JA et al. ("Resveratrol improves health and survival of mice on a high-calorie diet," Nature 444:337-342) reported that resveratrol fed at high doses (22 mg/kg/day, equivalent in body-surface scaling to about 1.5 g/day in a 70-kg human) to middle-aged mice on a high-fat diet produced a dramatic phenotypic shift. The treated mice maintained healthy mitochondrial function, normal insulin sensitivity, normal motor coordination, and normal lifespan compared to untreated high-fat-diet mice that became obese, diabetic, and died earlier. The mice on resveratrol essentially behaved as if they were on a normal-calorie diet despite eating the high-fat chow.

This was the headline finding that pushed resveratrol from academic curiosity to global supplement category. A second paper (Lagouge M et al., Cell 127:1109-1122, 2006) reported that resveratrol increased mitochondrial number, improved exercise endurance, and protected against diet-induced obesity in mice. Together, the 2006 mouse data made a compelling case that resveratrol was the closest molecular approximation to caloric restriction available to medicine.

Subsequent follow-up has been more nuanced. A 2008 study by the NIH's Intervention Testing Program found that resveratrol fed to normal-diet (non-obese) middle-aged mice did NOT extend lifespan, suggesting that the 2006 protective effect was specifically against the diet-induced metabolic disease, not a general lifespan-extending effect. This is an important distinction: resveratrol appears to protect against the metabolic insults of a poor diet, but it does not extend lifespan in already-healthy organisms.

For practical interpretation, this matters. If you eat a healthy diet, exercise, and maintain normal body weight, resveratrol may offer modest additive benefit but it is not a transformative intervention. If you are sedentary, eating poorly, or carrying excess weight, resveratrol may meaningfully mitigate some of the metabolic damage — but addressing the underlying diet and activity issues will dwarf any pharmacologic effect. The mouse data show resveratrol as a rescue medication for metabolic stress, not as a general longevity tonic.

Back to Table of Contents

How SIRT1 Actually Works (The Caloric Restriction Connection)

SIRT1 (silent information regulator 1) is the human homolog of yeast Sir2, the founding member of the sirtuin family of NAD+-dependent histone deacetylases. The enzyme removes acetyl groups from lysine residues on histones (the proteins that package DNA in chromatin) and on a large array of non-histone substrates, including key transcription factors. Because acetylation is generally an activating modification on regulatory proteins, deacetylation by SIRT1 silences or modifies the activity of its targets.

The substrates of SIRT1 that matter most for the longevity story are:

The SIRT1 connection to caloric restriction is straightforward: caloric restriction raises the cellular NAD+/NADH ratio (because fewer carbohydrates and fatty acids are being oxidized through the electron transport chain). NAD+ is the obligate cofactor for SIRT1 activity — the enzyme uses one molecule of NAD+ for every deacetylation reaction. So caloric restriction increases SIRT1 activity simply by providing more of its required cofactor. Resveratrol's effect appears to be a combination of (a) some direct allosteric enhancement of SIRT1's affinity for substrates and (b) indirect increases in NAD+ availability through AMPK pathway activation and altered NAD+ metabolism.

For the broader sirtuin family, SIRT3 is mitochondrial and regulates oxidative metabolism; SIRT6 is nuclear and regulates DNA repair and glucose metabolism; SIRT7 is nucleolar and regulates ribosomal RNA transcription. Resveratrol activates these to varying degrees, but the longevity research has focused primarily on SIRT1.

Back to Table of Contents

The Resveratrol — NAD — Sirtuin Axis

The longevity-focused supplement category that has grown up around resveratrol now centers on the broader NAD+ axis. NAD+ (nicotinamide adenine dinucleotide) is the obligate cofactor for all sirtuin reactions, and tissue NAD+ levels are known to decline with age — by some estimates, NAD+ falls by 50% between age 30 and age 70 in most tissues. The hypothesis is that age-related sirtuin underactivity is driven primarily by NAD+ depletion, and that restoring NAD+ levels is the key intervention.

This has driven enormous interest in NAD+ precursor supplements:

The contemporary "Sinclair stack" pairs resveratrol with NMN (or NR) on the theory that resveratrol provides the sirtuin pathway activation and NAD+ precursor provides the cofactor. Whether this combination outperforms either alone in humans is not established — long-term clinical trials with hard endpoints are still in progress. For our purposes, the relevant point is that Japanese knotweed extract provides the resveratrol arm of this stack, and the choice between knotweed extract and synthetic resveratrol comes down to whether you want the accompanying anthraquinones and polydatin from the knotweed matrix.

Back to Table of Contents

The Bioavailability Problem (Why Oral Dosing Underperforms)

The central problem with oral resveratrol is the staggering gap between (a) the concentrations needed to activate sirtuins in cell-culture experiments (typically 5 to 50 μM) and (b) the peak plasma concentrations achievable after oral dosing in humans (typically 50 to 200 nM of free resveratrol, even after a 1-g dose). The 100- to 1000-fold gap raises the obvious question of whether the in-vitro mechanisms translate at all to in-vivo effect in oral-dosed humans.

The explanation is rapid phase II metabolism. Resveratrol is absorbed efficiently from the small intestine — bioavailability of total resveratrol (free plus conjugated forms) is in the 70-80% range, which is excellent for any oral drug. The problem is what happens immediately after absorption. The molecule is a substrate for both UDP-glucuronosyltransferases (UGTs, primarily UGT1A1 and UGT1A9) and sulfotransferases (SULTs, primarily SULT1A1) in both the intestinal enterocyte and the liver. The result is rapid conjugation: within an hour of oral dosing, the vast majority of circulating resveratrol-derived material is present as glucuronide and sulfate conjugates, not as free resveratrol.

These conjugates were originally assumed to be biologically inactive (the standard textbook view of phase II conjugation). More recent work suggests that some conjugates retain measurable activity at certain targets and may even be deconjugated back to free resveratrol in target tissues by β-glucuronidase. The picture is incomplete but suggests that the conjugates may contribute to in-vivo effect more than the textbook model predicts.

Several formulation strategies have been developed to address bioavailability:

Back to Table of Contents

Polydatin as a Bioavailability Workaround

Polydatin (resveratrol-3-O-β-D-glucoside, also called piceid) is the glycoside form of resveratrol, in which a glucose molecule is attached to the resveratrol via a beta-glycosidic bond at the 3-position hydroxyl. The glycosylation has several practical pharmacokinetic consequences:

Some commercial knotweed products are now standardized to polydatin content rather than (or in addition to) resveratrol content. In whole-root knotweed, polydatin is actually present at higher concentrations than free resveratrol — the plant stores the molecule preferentially in the glycoside form. A traditional knotweed decoction or whole-root extract therefore delivers a meaningful polydatin dose alongside the free resveratrol, providing both immediate and sustained-release exposure.

The clinical research on polydatin specifically (as opposed to free resveratrol) is much smaller, but the existing trials suggest similar effects on inflammation, endothelial function, and oxidative stress — consistent with the molecule acting as a slow-release prodrug for resveratrol.

Back to Table of Contents

Human Clinical Trials — The Modest Reality

Despite the dramatic mouse data, human clinical trials of resveratrol have produced consistently modest results. The pattern is clear: statistically significant effects exist in many trials, but the effect sizes are small — nothing like the "extends life by 30%" framing that surrounds the mouse data.

Representative human trial findings:

The most negative trials have been in elderly subjects without baseline metabolic disease — the AESTHETIC and similar studies found minimal or no effect on cognitive function, body composition, or biomarkers in healthy older adults. This fits the broader pattern from the mouse data: resveratrol helps when there is metabolic stress to mitigate, but it does not add measurable benefit to already-healthy physiology.

Realistic effect-size expectations for resveratrol supplementation in adults:

These are real but modest effects. They are in the range of what dietary changes (Mediterranean-style eating), regular exercise, or weight loss produce — not in the range of pharmaceutical interventions for the same endpoints.

Back to Table of Contents

Stack Combinations (NR, NMN, Spermidine, Metformin)

The contemporary longevity-supplement landscape pairs resveratrol with several other interventions on the theory that they hit complementary mechanisms in the broader pathway. The most commonly stacked combinations:

For practical use, the realistic recommendation is to focus on one or two complementary interventions rather than building elaborate stacks. The longevity research field is in an early phase — we do not yet have human outcome data that justifies the more elaborate combinations being marketed.

Back to Table of Contents

Practical Dosing for Longevity Use

For users specifically interested in the longevity-pathway applications of resveratrol (rather than the broader Buhner Lyme protocol or traditional knotweed indications), the practical dosing range that has the most clinical-trial support is:

For users who want the knotweed-matrix form rather than purified resveratrol:

The doses commonly cited from David Sinclair's personal regimen (1 g/day) are at the upper end of what has been studied in long-term human trials. There is no compelling evidence that doses above 500 mg/day provide additional benefit, and the relationship between dose and effect appears to plateau or even reverse at high doses (the SRT501 micronized formulation produced gastrointestinal side effects and ultimately failed to show benefit in advanced colorectal cancer at gram-range doses).

Back to Table of Contents

Cautions and Realistic Expectations

Back to Table of Contents

Key Research Papers

  1. Howitz KT et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196. — PubMed
  2. Baur JA et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342. — PubMed
  3. Lagouge M et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127:1109-1122. — PubMed
  4. Pacholec M et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. JBC 285:8340-8351. — PubMed
  5. Walle T et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382. — PubMed
  6. Brasnyo P et al. (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106:383-389. — PubMed
  7. Timmers S et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612-622. — PubMed
  8. Tomé-Carneiro J et al. (2013). One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 110:356-363. — PubMed
  9. Sinclair DA, Guarente L (2014). Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 54:363-380. — PubMed
  10. Imamura H et al. (2017). Resveratrol attenuates triglyceride accumulation associated with upregulation of Sirt1 and lipoprotein lipase in 3T3-L1 adipocytes. Mol Genet Metab Rep. — PubMed
  11. Park SJ et al. (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421-433. — PubMed
  12. Hubbard BP, Sinclair DA (2014). Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 35:146-154. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents